FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D	.C. 20549
---------------	-----------

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Yan Ming						2. Issuer Name <b>and</b> Ticker or Trading Symbol Cytek Biosciences, Inc. [ CTKB ]										5. Relationship of Reporti (Check all applicable) X Director			son(s) to Iss			
(Last) (First) (Middle) C/O CYTEK BIOSCIENCES, INC.						ate of 18/20		est Tran	nsacti	ion (Mo	onth/	Day/Year)		helow)		le Other (sp below) hnology Officer		specify				
47215 LAKEVIEW BOULEVARD						4. If Amendment, Date of Original Filed (Month/Day/Year)										6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street)	NT CA	A !	94538													X Form filed by One Reporting Person  Form filed by More than One Reporting  Person						
(City)	(Si	rate)	(Zip)		Ru	Rule 10b5-1(c) Transaction Indication																
	Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.																					
		Tab	le I - No	n-Deriv	ative	Sec	urit	ies Ac	cqui	ired,	Dis	posed o	of, o	r Ber	neficial	ly Owne	t					
Date				2. Transa Date (Month/I		ır) Ei	2A. Deemed Execution Date, if any (Month/Day/Year)			3. Transac Code (li B)		4. Securi Disposed 5)	ties A I Of (I	Acquired D) (Inst	d (A) or r. 3, 4 and	4 and Securities Beneficially Owned Follo		Form (D) o	n: Direct r Indirect istr. 4)	7. Nature of Indirect Beneficial Ownership		
											v	Amount		(A) or (D)	Price	Reporte Transac (Instr. 3	tion(s)			(Instr. 4)		
Common	Stock			11/18	3/2023					M		1,981	L	Α	(1)	7,77	7,943		D			
Common	Stock			11/18	3/2023					F		772(2	)	D	\$5.9	8 7,77	77,171					
Common	Stock			11/18	3/2023					M		7,363	3	A	(1)	7,78	34,534	D				
Common	Stock			11/18	3/2023	2023		2023			F		2,431	(2)	D	\$5.9	8 7,78	7,782,103 D				
Common	Stock			11/20	)/2023					S <sup>(3)</sup>		20,00	0	D	\$6.03	(4) 7,76	52,103	D				
		Т	able II -									osed of onverti				Owned						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/Da	Date,	4. Transaction Code (Instr 8)				6. Date Exercis: Expiration Date (Month/Day/Yea			)	7. Title and Amount of Securities Underlying Derivative Sec (Instr. 3 and 4)		Security	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactic (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exe	e ercisabl		Expiration Date	Title		Amount or Number of Shares							
Restricted Stock Units	(1)	11/18/2023			M			1,981		(5)		(5)		nmon	1,981	\$0.00	17,180	)	D			
Restricted Stock	(1)	11/18/2023			M			7,363		(6)		(6)		nmon	7,363	\$0.00	98,179	,	D			

## **Explanation of Responses:**

- 1. Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.
- 2. Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award.
- 3. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2022.
- 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$5.88 to \$6.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- 5. The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18.

6. The shares subject to the RSU Award shall vest over four years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested.

## Remarks:

/s/ Valerie Barnett, Attorneyin-Fact for Ming Yan

11/21/2023

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.